Fierce Pharma
FEBRUARY 29, 2024
Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. | Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional.
Pharmaceutical Technology
FEBRUARY 29, 2024
India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 29, 2024
For the second time in four weeks, GSK has settled a personal injury lawsuit in California sta | For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac. The company revealed the dismissal of the case and the agreement in a release Thursday.
MedCity News
FEBRUARY 29, 2024
While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 29, 2024
As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie.
European Pharmaceutical Review
FEBRUARY 29, 2024
Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 29, 2024
Increasing costs and healthcare cybersecurity worries have sparked calls for new laws. The bipartisan “Strengthening Cybersecurity in Health Care Act” by four senators would require the HHS to perform routine evaluations of its systems and deliver biannual reports on practices and progress.
Fierce Pharma
FEBRUARY 29, 2024
Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers | Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers in Florida.
Pharmaceutical Technology
FEBRUARY 29, 2024
LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.
Fierce Pharma
FEBRUARY 29, 2024
Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in | Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in the past.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
FEBRUARY 29, 2024
Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
Fierce Pharma
FEBRUARY 29, 2024
Editor's note: This story was updated to note that Endo's criminal and civil opioid settlement payments will be satisfied by the bankruptcy resolution, according to an Endo | As it looks to emerge from bankruptcy, Endo agreed to fork over up to $464.9 million to the federal government, which had been investigating the marketing of opioid Opana ER.
MedCity News
FEBRUARY 29, 2024
Telehealth is great at expanding access to care, but sometimes the quality isn’t there, according to Dr. Pat Carroll, chief medical officer of Hims & Hers.
Fierce Pharma
FEBRUARY 29, 2024
Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. | The company is quickly moving through Elevidys' eligible patient population while awaiting the FDA's decision on a broader label. In the fourth quarter, the gene therapy pulled down $131 million in sales.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
FEBRUARY 29, 2024
Last year, in agreeing to acquire Reata Pharmaceuticals for $7.3 billion , Biogen gained rights to SKYCLARYS ® (omaveloxolone), the first approved treatment for the rare disease Friedreich’s ataxia. The Committee for Medicinal Products for Human Use (CHMP) recently recommended the approval of several therapies for rare diseases, including the first oral treatment against residual haemolytic anaemia in the rare blood disorder, paroxysmal nocturnal haemoglobinuria, as well as the first therapy to
Fierce Pharma
FEBRUARY 29, 2024
BeiGene expanded its global workforce by 1,400 over the past 12 months amid fast revenue growth. | BeiGene expanded its global workforce by 1,400 over the past 12 months. Bristol Myers Squibb opened a large innovation hub in India. AstraZeneca has decided to hold onto Evrenzo in China and Korea while returning rights to FibroGen in the U.S.
pharmaphorum
FEBRUARY 29, 2024
On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.
Pharmaceutical Technology
FEBRUARY 29, 2024
Amyotrophic lateral sclerosis (ALS) is a swiftly advancing, fatal neurodegenerative condition marked by muscle weakness, atrophy, and spasticity.
Copyright Clearance Center
FEBRUARY 29, 2024
A joint statement from major international publishing bodies appeals to South Africa's National Assembly to vote down its copyright bill…
Pharmaceutical Technology
FEBRUARY 29, 2024
The NHS has expedited the availability of the new drug, Belumosudil for cancer patients with chronic graft versus host disease (GVHD).
pharmaphorum
FEBRUARY 29, 2024
Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.
Pharmaceutical Technology
FEBRUARY 29, 2024
The US HHS Secretary called for state collaboration on a project to improve gene therapy access for sickle cell disease.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
FEBRUARY 29, 2024
Ironwood Pharma says phase 3 trial of apraglutide in short bowel syndrome (SBS) hit it main endpoint, but missed secondary outcomes weigh on its share price
PharmaVoice
FEBRUARY 29, 2024
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
pharmaphorum
FEBRUARY 29, 2024
Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for routine use by the NHS in England and Wales.
MedCity News
FEBRUARY 29, 2024
Adopting an infinite mindset could be the antidote to the slow destruction of healthcare by short-term thinking.
PharmaTimes
FEBRUARY 29, 2024
Aphasia is a language disorder caused by some form of brain damage, including stroke
MedCity News
FEBRUARY 29, 2024
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Clarivate
FEBRUARY 29, 2024
Around the world, college students are struggling post-pandemic. In the U.S. the national average score on the ACT college placement exam declined to its lowest point in 30 years. In the U.K., researchers are warning that higher ed students are facing increased pressures that significantly reduce their resilience. In the classroom, faculty are reporting high levels of absenteeism and low levels of engagement.
pharmaphorum
FEBRUARY 29, 2024
Generic and biosimilar drugmaker Sandoz has agreed to pay $265 million to settle allegations of price-fixing in a Pennsylvania lawsuit.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
277 
Let's personalize your content